Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
While current treatment modalities have greatly improved prognoses for most patients, a significant number present clinical symptoms of acromegaly with elevated levels of IGF-1 in the absence of increased GH levels, a phenomenon known as micromegaly.
|
31071497 |
2020 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A univariate analysis was conducted and eight features, including age, hypertension, ophthalmic disorders, GH, IGF-1, nadir GH, maximal tumor diameter, and Knosp grade, were significantly associated with the TSS response in patients with acromegaly.
|
31673954 |
2020 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Achieving biochemical control (normalization of insulin-like growth factor-1 [IGF-1] and growth hormone [GH]) is a key goal in acromegaly management.
|
31741320 |
2020 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mean age of the 30 acromegaly patients (M/F:14/16) was 47.26 ± 12.52 years (range: 18-64 years) and that of the healthy volunteers (M/F: 17/13) was 44.56 ± 10.74 years (range: 19-62 years).Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels were measured using an electrochemiluminescence method, and serum sclerostin levels using an enzyme-linked immunosorbent assay.The Mann-Whitney U test was used to compare sclerostin levels between the two groups.
|
31821453 |
2020 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The paradoxical GH response reflected the clinical characteristics, especially IGF-I level, glucose metabolism, and drug efficacy in acromegaly.
|
30476255 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred acromegaly patients on medical therapy (mean age = 47.1 years; SD = 11.96) completed an online preference study evaluating hypothetical patient profiles described in terms of insulin-like growth factor-I (IGF-I) levels, tumor size, comorbid conditions, signs/symptoms, and quality of life (QoL).
|
30627944 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Background Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated with persistent impairment of trabecular microstructure leading to increased risk of vertebral fractures.
|
30640713 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, routine screening of GD should be considered in women with acromegaly, particularly in those with risk factors for GD and with uncontrolled IGF-1 levels before pregnancy.
|
31520541 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is characterized by an excess of growth hormone (GH) and insulin like growth-factor 1 (IGF1).
|
31751301 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
We will focus on the issues regarding the measurement and interpretation of IGF-I concentrations in the management of acromegaly patients.
|
30311754 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Incidence of mortality, its correlation with GH (cumulative exposure vs last value), and IGF-I levels and the shift in the main cause of mortality in patients with acromegaly are also addressed.
|
30184064 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Suppressor of cytokine signaling (SOCS) 2, a negative regulator of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), which is associated with acromegaly and cancers, is a promising candidate molecule for treating various diseases.
|
30343638 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor 1 (IGF-1) assay should be used as a screening test whenever acromegaly is suspected.
|
30843181 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Between PTC group without acromegaly and APTC, galectin 3 and IGF1 expression was significantly higher in acromegalic patients (p<0.01 for all) while RAS was predominantly higher in PTC patients without acromegaly (p<0.01).
|
29890543 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The participants of the study were divided into 3 groups as the control (Group-I), acromegaly patients with remission (Group-II), and acromegaly patients without remission (Group-III).Insulin growth factor-1 (IGF-1) level significantly increased from Group-I to Group-III.
|
30653179 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is associated with clinically high IGF-I concentrations.
|
31755099 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Treatments used to normalize IGF-I levels in patients with acromegaly could have differential effects on cardiovascular risk factors and metabolic parameters.
|
30397873 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin-like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity.
|
30843342 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA).
|
30772778 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
We studied 23 patients with active acromegaly before and for ≤2 years after surgical (n = 13) or GH receptor antagonist therapy with pegvisomant (n = 10), and 100 healthy subjects with morning fasting blood samples for AgRP, leptin, GH, and IGF-1 and anthropometric measurements.
|
31361303 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured serum levels of GH, IGF-1, sDlk1 and sKlotho (both by ELISA) in 42 treatment-naïve acromegaly patients (20 females/22 males) before and 1-3 months after transsphenoidal surgery.
|
30818110 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is known to be associated with high incidence of malignancies probably due to the mitogenic effects of IGF-1.
|
31185505 |
2019 |
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have shown that increased life expectancy in acromegaly patients who attain normal GH and IGF-I levels is associated with more deaths due to age-related cancers.
|
30500870 |
2019 |
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
No significant correlation was found between IGF-1 ULN and QoL scores in acromegaly.
|
30548674 |
2019 |
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the pathophysiology of endothelial dysfunction in the condition of GH and IGF-1 excess remains a crucial area of investigation to fully dissect the association of acromegaly with cardiovascular disease complications.
|
31396153 |
2019 |